New Dual-Chamber Syringe for Xyntha

Horizons in Hemophilia, November 2010

By Leigh Carpenter, RPh, Chief Pharmacist

In August, Pfizer, Inc. (formerly Wyeth), announced the U.S. Food and Drug Administration (FDA) granted approval for the use of a new administration device for Xyntha, the company’s recombinant factor VIII product.  Xyntha will now be dispensed with a prefilled dual-chamber syringe for intravenous administration.  Both the Xyntha powder and the sterile diluent are supplied within this syringe, eliminating the transfer step from vial to syringe.  The first dosage size available is the 3000u.  Other dosages of Xyntha (250u, 500u, 1000u & 2000u) will be available in the prefilled dual-chamber syringe in 2011.  Pfizer believes this new reconstitution system will offer patients more convenience, thus saving time and effort with infusions.  If you are interested in learning more about this product or device, please talk to your Hemophilia Treatment Center or the HoG/Beacon Pharmacies.